Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions

Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14.
No abstract available

Keywords: T- LGL; alemtuzumab; aplastic anaemia; bone marrow failure; pure red cell aplasia.

Publication types

  • Clinical Study
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alemtuzumab / administration & dosage*
  • Alemtuzumab / adverse effects
  • Anemia, Aplastic / drug therapy
  • Bone Marrow Diseases / drug therapy*
  • Bone Marrow Diseases / etiology
  • Bone Marrow Diseases / mortality
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Large Granular Lymphocytic / drug therapy
  • Male
  • Middle Aged
  • Red-Cell Aplasia, Pure / drug therapy
  • Salvage Therapy / methods
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Substances

  • Alemtuzumab